HrC Cancer
Monitoring
Program
The Only Way to Beat
Cancer is to Catch it Early
HrC Cancer Monitoring Program
- Utilises Advanced HrC Technology
- Simple Blood Test
- Monitors for Early Indicators of Cancer
- Assesses Risk of Cancer Presence
- Identifies 'Absence' of Cancer
- 60+ Different Types of Cancer
- Accurate & Reliable Results
- Results Issued within 6/8 Weeks
- Edison Gold Award Winners 2025
From £1299pp. Price includes:
- Blood Draw at a Central London Clinic
- Same Day Collection/Delivery to Laboratory
- Isolation & Enrichment of Cells of Interest
- RNA Extraction from Cells of Interest
- Sample Processing Using NGS Technology
- Bioinformatic Analysis of NGS Data
- Data Interpretation by Cancer Scientists
- Issuing of HrC Genomics Test Report
- Post-Consultation with Private GP for Positive Results
How HrC Works
The HrC Cancer Monitoring Program utilises advanced blood-based technology to identify and monitor the early indicators of cancer.
From a patient’s blood sample, we can:
- Identify if there is “no risk” of cancer presence (which also suggests a negligible risk of developing cancer within the following one year).
- Assess existing risk of cancer presence which can vary from negligible, low, moderate, to high.
A “no risk” score from indicates that the molecular markers being tracked are within the range of a healthy individual who is cancer-free, with no previous history of cancer.
Further information about HrC and the science behind the technology can be found here.
Joining The Program
The first step to joining the HrC Cancer Monitoring Program is to check if you are eligible to take the HrC test using the Eligibility Checker. Once you have submitted your answers, you will receive a response by email confirming your Eligibility Status.
If Eligibility is confirmed then the email will also contain details on how to proceed.
If Eligibility is not Confirmed then the email will include an explanation to why the HrC test is not suitable for you.
Who We Can Help
Asymptomatic Patients
- Evaluate current risk of cancer presence.
- Detect early molecular or cellular changes associated with pre-symptomatic cancer development.
- Provide early molecular indicators for clinical correlation.
- Differentiate benign or malignant tumour condition from healthy population.
- Identify precancerous conditions amenable to preventive treatment. Early-stage interventions can improve therapeutic response.
- Contribute to better health economics through earlier disease detection.
- Identify high-risk population requiring close and periodic monitoring.
- Enable large-scale, population-level health surveillance.
Suitable For:
- Asymptomatic individuals seeking preventive assessment.
- Symptomatic individuals wanting to assess underlying triggers, if any.
- Individuals with a known family history of cancer.
Enjoy peace of mind through knowing that your cancer risk is being monitored on an annual basis. The only way to beat cancer is to catch it early. The only way to proactively catch cancer early is to monitor for its presence.
Cancer Patients
Monitoring Responsiveness to Treatment
- Assess therapeutic response at pre-, during-, and post-treatment stages.
- Monitor individualised treatment effectiveness.
- Enhance survival outcomes through early recognition of treatment resistance or response.
Suitable For:
- Patients currently receiving active therapy for cancer.
Cancer Survivors
Confirming Remission
Why monitor for cancer post-remission?
- Monitor remission status following completion of therapy.
- Detect early recurrence and improve post-remission survival rates.
- Identify secondary malignancies or metastatic reactivation.
- Support long-term health tracking and enhance quality of life.
Suitable For:
- Cancer survivors who have been disease-free for at least six months after treatment completion.
